Abstract
Epstein-Barr virus (EBV) is a gamma herpesvirus that causes a life-long latent infection in human hosts. The latent gene products LMP1, LMP2A and EBNA1 are expressed by EBV-associated tumors and peptide epitopes derived from these can be targeted by CD8 Cytotoxic T-Lymphocyte (CTL) lines. Whilst CTL-based methodologies can be utilized to infer the presence of specific latent epitopes, they do not allow a direct visualization or quantitation of these epitopes. Here, we describe the characterization of three TCR-like monoclonal antibodies (mAbs) targeting the latent epitopes LMP1125–133, LMP2A426–434 or EBNA1562–570 in association with HLA-A0201. These are employed to map the expression hierarchy of endogenously generated EBV epitopes. The dominance of EBNA1562–570 in association with HLA-A0201 was consistently observed in cell lines and EBV-associated tumor biopsies. These data highlight the discordance between MHC-epitope density and frequencies of associated CTL with implications for cell-based immunotherapies and/or vaccines for EBV-associated disease.
Highlights
Epstein-Barr virus (EBV) is a gamma herpesvirus that causes a life-long latent infection in human hosts
The latent gene products Latent Membrane Protein 1 (LMP1), Latent Membrane Protein 2A (LMP2A) and Epstein-Barr Virus Nuclear Antigen 1 (EBNA1) are expressed by EBV-associated tumors and peptide epitopes derived from these can be targeted by CD8 Cytotoxic T-Lymphocyte (CTL) lines
The virus can infect cells of both lymphoid and epithelial origin and its latent infection phase is associated with malignancies that arise from these cell types, including Non-Hodgkin’s lymphoma, Hodgkin’s Lymphoma[2] and undifferentiated nasopharyngeal carcinoma (NPC)[3]
Summary
Epstein-Barr virus (EBV) is a gamma herpesvirus that causes a life-long latent infection in human hosts. We describe the characterization of three TCR-like monoclonal antibodies (mAbs) targeting the latent epitopes LMP1125–133, LMP2A426–434 or EBNA1562–570 in association with HLA-A0201 These are employed to map the expression hierarchy of endogenously generated EBV epitopes. Despite the subdominant frequencies of CTLs specific for epitopes derived from these latent gene products (0.05%–1%), they are implicated in the control of EBV infection in vivo[1] The presence of these gene products in the majority of EBV-associated tumors suggests that an analysis of their associated CTL epitopes is essential for the design of immuno-targeting approaches including adoptive T-cell therapy. Antibodies targeting epitopes of EBV latent gene products (LMP1125–133, LMP2A426–434 and EBNA1562–570) were generated and characterized This allowed an analysis of viral epitope expression using a combination of immunological and biochemical methods www.nature.com/scientificreports including flow cytometry, immunohistochemical staining, and confocal microscopy. Our observations of this hierarchy and its differential binding on strain-associated epitope variants have important implications for diagnosis, immuno-targeting and vaccine development
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
